Abstract
256 Background: Although FOLFIRINOX is superior to gemcitabine in MPC, the regimen is associated with significant toxicities (Conroy et al. N Engl J Med 2011;364:1817). In our prior retrospective a...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have